Ensuring re-treatment for hepatitis C

July 2023: During the data collection process data enumerator came across one person who had failed an earlier treatment of HCV. Due to stock issues of sofosbuvir/velpatasvir regimen his possible re-treatment was deferred.

Action taken: A meeting was convened with the State Nodal Officer of the viral hepatitis program for alternative arrangement of the medicine. The program provided the medicine to the patient by reallocating the required DAA drugs from other district hospital. The person has initiated his re-treatment of HCV with Sofosbuvir/velpatasvir along with Ribavirin for 12 weeks on the advice of the doctor at the treatment center in October 2023.